– USA, NC – Polarean Imaging plc (LON: POLX) the medical‑imaging technology company today announced the appointment of Frank Schulkes to its Board as a Non-Executive Director with immediate effect.
“Frank is a seasoned financial expert and his broad background in corporate finance will be a great benefit as he takes the role as Chair of our Audit Committee. I am delighted that he has agreed to join us in a Non-Executive Director role, and we look forward to capitalising on his excellent track record and hearing his independent views in addition to those already providing guidance to the management team. On behalf of the Board, I would like to welcome Frank to the team at Polarean and we look forward to the skills and advice he will bring to the Company.” said CEO, Richard Hullihen.
Mr. Schulkes will also join the Audit Committee as Chair.
About Frank Schulkes
Frank Schulkess has previously spent 27 years with GE, of which 18 of those were with GE Healthcare, a global medical technology, life sciences, and services organization, in a variety of increasingly senior financial and planning roles. In 2007, he was appointed EVP and CFO of GE Healthcare, a position he held for eight years.
Most recently, Mr. Schulkes was CFO of ConvaTec Group Plc., a global medical products and technologies company focused on therapies for the management of chronic conditions, with leading market positions in advanced wound care, ostomy care, continence & critical care, and infusion care. Before that, he was CFO of Wittur Group, a privately-held industrial company based in Germany.
Frank Schulkes said: “I am thrilled to join the Polarean Board and I am keen to use my experience in a long career in finance to add value to the team.”
About Polarean
The Company and its wholly-owned subsidiary, Polarean, Inc. are revenue-generating, investigational drug-device combination companies operating in the high-resolution medical imaging research space.
The Group develops equipment that enables existing MRI systems to achieve an improved level of pulmonary function imaging and specializes in the use of hyperpolarised Xenon gas as an imaging agent to visualize ventilation. 129Xe gas is currently being studied for visualization of gas exchange regionally in the smallest airways of the lungs, across the alveolar tissue membrane, and into the pulmonary bloodstream.
In October 2020, the Group submitted a New Drug Application to the FDA for hyperpolarised 129Xe used to evaluate the pulmonary function and to visualize the lung using MRI. The Group received a complete response letter on 5 October 2021. On 30 March 2022, the Company filed the resubmission of its NDA with the US FDA.
The Group operates in an area of significant unmet medical need and the Group’s technology provides a novel investigational diagnostic approach, offering a non-invasive and radiation-free functional imaging platform. The annual economic burden of pulmonary disease in the US is estimated to be over $150 billion.
For more information: https://polarean.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
